Publicacións en colaboración con investigadores/as de Pfizer (United States) (2)

2024

  1. Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy

    ESC Heart Failure

  2. REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNARelated Dilated Cardiomyopathy

    Circulation: Heart Failure, Vol. 17, Núm. 7, pp. e011548